Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

CD55 / Decay Accelerating Factor (DAF) Antibody [143-30]

In Stock
Catalog Number Formulation Size Price
1604-MSM2-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
1604-MSM2-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
1604-MSM2-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol
Flow Cytometry (Flow)
1-2ug/million cells
Immunofluorescence (IF)
1-3ug/ml

Summary

Recognizes a single chain glycoprotein of 70kDa, identified as CD55/DAF. It is widely expressed on cells throughout the body including leukocytes, erythrocytes, epithelium, endothelium, and fibroblasts. It is a Glycosyl phosphatidylinositol anchored (GPI-anchored) member of the membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. It prevents the amplification steps of the complement cascade by interfering with the assembly of the C3-convertases, C4b2a and C3bBb, and the C5-convertase, C4b2a3b and C3bBb3b. CD55 also serves as receptor for CD97 and for echovirus and Coxsackie B virus. The MAb 143-30 may be used as marker for paroxysmal nocturnal hemoglobinuria (PNH).

Product Properties & Targets

Antibody Type
Host
Mouse
Species Reactivity
Isotype / Light Chain
IgG1 / Kappa
Cellular Localization
Cell membrane, Secreted
Gene Name
Positive Control
Jurkat cells or human lymphocytes. Human lymph nodes and tonsils.
Immunogen
PHA stimulated human PBL
Alternate Names
Complement decay-accelerating factor, CD55; CD55 Cromer blood group system; Complement decay-accelerating factor; CROM; DAF; GPI-DAF; Decay Accelerating Factor for Complement; Decay accelerating factor GPI-form; Decay accelerating factor soluble-form

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
143-30
Chromosome Location
1q32
Mol. Weight of Antigen
70kDa

Functions

  • This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829).
  • (Microbial infection) Acts as a receptor for Coxsackievirus A21, coxsackieviruses B1, B3 and B5.
  • (Microbial infection) Acts as a receptor for Human enterovirus 70 and D68 (Probable).
  • (Microbial infection) Acts as a receptor for Human echoviruses 6, 7, 11, 12, 20 and 21.

Key References

  • Kishimoto T. et al., eds. Leukocyte Typing VI, Garland Publishing, Inc, New York and London, 1997.Koretz, K. et al., Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. British J. Cancer 66: 810-814, (1992).

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “CD55 / Decay Accelerating Factor (DAF) Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK